CANTON, Mass., Aug. 3 /PRNewswire/ -- Another sign that oral-based drug testing is swiftly gaining worldwide acceptance, came today as Avitar (Amex: - ) announced that The Egyptian International Company for Environmental Protection (EICEP), its distribution partner in Egypt, has secured several agreements that will sell Avitar's ORALScreen® products in Jordan, Kuwait, Saudi Arabia and other countries in the Middle Eastern region.
"We are encouraged by the positive response that we have received from our business partners and end users," stated Peter P. Phildius, Chairman and CEO of Avitar. "We are pleased that EICEP has expanded its distribution network and already secured multiple end-user clients in the Middle East. Oral fluid- based drug testing has many advantages over urine-based testing and we expect to see accelerated growth as more people learn about the inherent benefits of oral fluid based drug testing."
"We chose to partner with Avitar based on its ORALScreen technology platform and technical support capabilities," said Tony Kassem, Chief Financial Officer and Partner of EICEP. "We believe that oral-based drug testing is far superior to other drug testing methods and we have been tremendously pleased with the response we have had as more and more individuals learn about the convenience, accuracy, and effectiveness associated with oral fluid based drug testing. Our expansion into additional countries in the region signifies the potential of oral fluid drug testing in the Middle East."
According to EICEP's forecasts, the distribution agreement may represent revenue of $3.5 million USD for Avitar over the next three years. Current clients in the region include major oil and manufacturing companies, as well as services firms.
Avitar, Inc. develops, manufactures and markets innovative and proprietary products. Their field includes the oral fluid diagnostic market, the disease and clinical testing market, and customized polyurethane applications used in the wound dressing industry. Avitar manufactures ORALscreen®, the world's first non-invasive, rapid, onsite oral fluid test for drugs-of-abuse, as well as HYDRASORB®, an absorbent topical dressing for moderate to heavy exudating wounds. Avitar is also developing diagnostic strategies for disease and clinical testing in the estimated $25 billion in-vitro diagnostics market. Conditions targeted include influenza, diabetes, and pregnancy. For more information, see Avitar's website at https://avitarinc.com.
The Egyptian International Company for Environmental Protection (EICEP) is a multi-disciplinary technical services and consulting firm. EICEP is a leader in exploring new ideas, investing in advanced technologies, taking responsibility for the environment and harnessing innovation for a competitive advantage.
Safe Harbor Statement.
This release contains forward looking statements that are subject to risks and uncertainties including the development and marketing of new applications and other risks that are detailed from time to time in the Company's filings with the Securities and Exchange Commission. In view of such risks and uncertainties, the Company's actual results could differ materially from those anticipated in such forward looking statements.
Company Contact: PR Contact:
Peter Cholakis Monica Pandolfi
Avitar Inc. SHIFT Communications